Key facts
- OrbitalRx’s last known valuation is $25.2M (Oct 2025).
- It has raised $7.4M across 6 recorded rounds; the latest was Seed Round ($1.2M) in Aug 2025.
- Notable investors include Hatteras Venture Partners, Triangle Angel Partners, Alerion Ventures, Boston Millennia Partners, Excelerate Health Ventures — 7 tracked in total.
- OrbitalRx has filed 8 Form Ds with the SEC since 2018, most recently Mar 2025 ($959K sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for OrbitalRx
Funding rounds
6 roundsAbout OrbitalRx
Developer of drug shortage management software designed to assist the hospital pharmacy team in improving medication shortages. The company's software facilitates users in visualizing, optimizing, and customizing a portfolio of pharmacy automation systems regardless of vendor, enabling healthcare professionals to manage the workflow and data challenges of ongoing medication shortages.
- Sector
- Healthcare
- HQ
- Winston-Salem, NC, United States
- Founded
- 2017
- Employees
- 17
- Website
- orbitalrx.com/
- Ownership
- Privately Held (backing)
OrbitalRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OrbitalRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OrbitalRx in its N-PORT filings yet. We sweep new filings monthly.